Switchgear Monitoring System Market to Witness Steady Growth with a Market Value of US$2.04 Billion by 2033, Persistence Market Research
April 19, 2023 09:10 ET
|
Persistence Market Research
New York, April 19, 2023 (GLOBE NEWSWIRE) -- The Global Switchgear Monitoring System Market size was valued at USD 1.26 billion in 2022 and is Projected to reach USD 2.04 billion by 2033, growing at...
New research reveals shifting identities of global fishing fleet to help bolster fisheries management
January 18, 2023 15:27 ET
|
Global Fishing Watch
WASHINGTON, D.C., Jan. 18, 2023 (GLOBE NEWSWIRE) -- A new study published today in Science Advances combines a decade’s worth of satellite vessel tracking data with identification information from...
Emerging technology gives first ever global view of hidden vessels
June 08, 2022 00:01 ET
|
Global Fishing Watch
Washington, D.C., June 08, 2022 (GLOBE NEWSWIRE) -- Global Fishing Watch has developed and publicly released the first ever global map of previously undetected dark fleets, or vessels that do not...
OmniMesh Taps AIS for Cybersecurity in its Content Delivery Solutions
September 24, 2019 10:21 ET
|
OmniMesh
Addition of world-class, defense-grade security assures privacy and security in content management Syracuse, NY, Sept. 24, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- OmniMesh, a leader in...
DiaMedica Therapeutics to Present at Lake Street’s 3rd Annual Best Ideas Growth (BIG3) Conference on September 12, 2019
September 06, 2019 09:00 ET
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Sept. 06, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that management will attend the Lake Street Capital Markets 3rd Annual Best Ideas Growth...
DiaMedica Therapeutics to Present at the 2019 Dougherty & Co. Institutional Investor Conference
September 03, 2019 16:15 ET
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Sept. 03, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that management will present at the 2019 Dougherty & Co. Institutional Investor...
DiaMedica Therapeutics Announces Second Quarter 2019 Financial Results and Provides Business Update
August 13, 2019 16:35 ET
|
DiaMedica Therapeutics Inc.
Phase Ib study of DM199 in Chronic Kidney Disease enrollment completeEncouraging early signals in mechanism biomarkers (NO and PGE2), Kidney function (eGFR) and urine albumin (UACR) Phase II...
DiaMedica Therapeutics to Present at the 2019 Intellisight Investor Conference on August 14, 2019
August 12, 2019 08:00 ET
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Aug. 12, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that Rick Pauls, President and CEO, will be presenting at the 2019 Intellisight Conference,...
DiaMedica Therapeutics to Report Second Quarter 2019 Financials and Provide a Business Update August 13, 2019
August 08, 2019 16:00 ET
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Aug. 08, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its second quarter 2019 financial results will be released after the markets close on...
DiaMedica Therapeutics Announces Interim Results from Phase 1b Trial of DM199 in Chronic Kidney Disease Participants
June 19, 2019 16:04 ET
|
DiaMedica Therapeutics Inc.
Favorable DM199 safety profile across tested dosesPharmacodynamic results helped identify dose range for Phase II studiesEncouraging early signals in mechanism biomarkers (NO and PGE2), Kidney...